Enviaments recents

PARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric survey

Turinetto, Margherita; Marchetti, Claudia; Scandurra, Giuseppa; Colombo, Nicoletta; cormio, gennaro; Cecere, Sabrina Chiara; Barberi, Vittoria (Data de publicació: 2026-03-04)

PARPi; Ovarian cancer; Therapy-related myeloid neoplasms

Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer

Morganti, Stefania; Kusmick, Ross J.; Hughes, Melissa E.; Smith, Kalie; Vega-Leon, Rosario; Brasó Maristany, Fara; Tarantino, Paolo (Data de publicació: 2026-03-02)

Antibody-drug conjugates; Biomarkers; Metastatic breast cancer

HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy

Nozawa, Kazuki; Sawaki, Masataka; Uemura, Yukari; Tsuneizumi, Michiko; Takano, Toshimi; Gondo, Naomi; Villacampa Javierre, Guillermo (Data de publicació: 2026-03-03)

Older patients; HER2-positive breast cancer; Chemotherapy

Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study

Baharloo , Kimiya; Kato, Ken; Shen, Lin; Enzinger, Peter; adenis, antoine; Sun, Jong-Mu; Alsina, Maria (Data de publicació: 2026-03-03)

Chemotherapy; Esophageal cancer; Pembrolizumab

CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1

Van Laethem, Jean-Luc; Geboes, Karen; Borbath, Ivan; Lambert, Aurélien; Macarulla, Teresa; CASSIER, Philippe (Data de publicació: 2026-01-27)

CD40 agonist; Biomarker; Chemotherapy

Sex differences in the incidence trends of early-onset gastrointestinal cancer—the European/Mediterranean perspective

Ben-Aharon, Irit; Fokter Dovnik, Nina; Guren, Marianne; Gordon, Noa; van Laarhoven, H.W.M.; Baraibar, Iosune (Data de publicació: 2026-01-27)

Sex differences; Early-onset gastrointestinal cancer

Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5

Gazzah, A.; Ricordel, Charles; Calvo, Emiliano; ITALIANO, ANTOINE; Cho, Byoung Chul; Kim, Dong-Wan; Vieito , Maria (Data de publicació: 2026-01-27)

Antibody-drug conjugate; Carcinoembryonic antigen-related cell adhesion molecule 5; Non-small cell lung cancer

Competencies for bioinformatics core facility scientists: extension of the ISCB competency framework for bioinformatics

Lloret-Llinares, Marta; Carvajal-López, Patricia; Downing, Tim; Gogol, Madelaine; Ho Sui, Shannan; Nonell, Lara (Data de publicació: 2026-01-27)

Competencies; Bioinformatics

USP10/GSK3β-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer

Kumari, Nishi; Wright, Sarah Christine Elisabeth; Witham, Christopher; Monserrat, Laia; Palafox Sánchez, Marta; Richard, John L. C.; Serra, Violeta (Data de publicació: 2025-11-25)

Breast cancer; Cell biology; Oncology

Breastfeeding after breast cancer in young BRCA carriers

DELUCCHI, VIRGINIA; Ferrari, Alberta; Blondeaux, Eva; Mariamidze, Elene; Bernstein Molho, Rinat; Frank, Sophie; Balmaña, Judith (Data de publicació: 2025-11-24)

Breastfeeding; Breast cancer; BRCA carriers

Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc

Takekuma, Munetaka; Nishio, Shin; Yamaguchi, Satoshi; Yunokawa, Mayu; Nishio, Hiroshi; Nishino, Koji; Villacampa Javierre, Guillermo; OAKNIN, ANA (Data de publicació: 2025-11-24)

Angiogenesis Inhibitors; Atezolizumab; Bevacizumab

Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914)

Hernando, Jorge; BENAVENT VIÑUALES, MARTA; Capdevila Castillon, Jaume; Molina-Cerrillo, Javier; Garcia-Carbonero, Rocio; Teule, Alex (Data de publicació: 2025-11-21)

Cabozantinib; Atezolizumab; Advanced progressive endocrine malignancies

Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer

Even, Caroline; Massarelli, Erminia; Laban, Simon; FAYETTE, Jérôme; Oliva Bernal, Marc; Harrington, Kevin; Brana, Irene (Data de publicació: 2025-11-11)

Combination therapy; Head and neck cancer; Immune checkpoint inhibitor

Retreatment with oxaliplatin-based regimens in refractory metastatic colorectal cancer: characterization of high-response patients

Catani, Greta; Alcaraz Soler, Adriana; García, Ariadna I.; Elez, Elena; Salvà, Francesc; Saoudi Gonzalez, Nadia; Baraibar, Iosune; Ros, Javier; R Castells, Marta; Salva de Torres, Clara; Comas Navarro, Raquel; Ruiz Pace, Fiorella; Rezqallah Arón , María Alejandra; Dienstmann, Rodrigo; Tabernero, Josep (Data de publicació: 2025-11-10)

Oxaliplatin; Rechallenge; Reintroduce

Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases—the PURPLE trial

Elez, Elena; Neumann, Ulf; Lang, Sven Arke; Trampe, A. K.; Kasper, Stefan; Salvà, Francesc (Data de publicació: 2025-11-07)

Colorectal liver metastases; Preoperative immunotherapy; Atezolizumab

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer

Moore, Kathleen; FABBRO, MICHEL; OMalley, David; Grisham, Rachel; Monk, Bradley; Van Nieuwenhuysen, Els (Data de publicació: 2025-11-06)

Ovarian Cancer

Clinical validation of liquid biopsy-RECIST (LB-RECIST) in metastatic colorectal cancer (mCRC) patients: findings from the PLATFORM-B study

MARTELLI, VALENTINO; vidal barrull, joana; Gibert Fernandez, Joan; Fernandez-Rodriguez, Concepción; Linares, Jenniffer; Elez, Elena; García-Alfonso, Pilar; Toledo, Rodrigo; Tabernero, Josep (Data de publicació: 2025-11-05)

Liquid biopsy; Metastatic colorectal cancer; Response assessment

Epigenetic synthetic lethality as a cancer therapeutic strategy: synergy of experimental and computational approaches

Fariña Morillas, Maria; Ollé i Monràs, Laia; de Rojas de Pablo, Isabel; Seoane Fernández, Jose Antonio; Maas, Silvana; Segura, Miguel F. (Data de publicació: 2025-11-03)

Synthetic lethality; Chromatin remodeling; Epidrugs

Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE

Naume, Bjørn; wildiers, hans; Sonke, Gabe; Karakatsanis, Andreas; Matikas, Alexios; DIECI, MARIA VITTORIA; Villacampa Javierre, Guillermo (Data de publicació: 2025-10-30)

Breast tumours; Drug therapy

Spatial TCR clonality and clonal expansion in the in situ microenvironment of non-small cell lung cancer

Yu, Hui; Magoulopoulou, Anastasia; Amini, Rose-Marie; Chatzinikolaou, Maria Paraskevi; Horie, Masafumi; Lindberg, Amanda; Mezheyeuski, Artur (Data de publicació: 2025-10-30)

Clonality; Immune Checkpoint Inhibitor; Lung Cancer

Articles científics - VHIO: Enviaments recents

PARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric survey ﻿

Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer ﻿

HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy ﻿

Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study ﻿

CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1 ﻿

Sex differences in the incidence trends of early-onset gastrointestinal cancer—the European/Mediterranean perspective ﻿

Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 ﻿

Competencies for bioinformatics core facility scientists: extension of the ISCB competency framework for bioinformatics ﻿

USP10/GSK3β-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer ﻿

Breastfeeding after breast cancer in young BRCA carriers ﻿

Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc ﻿

Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914) ﻿

Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer ﻿

Retreatment with oxaliplatin-based regimens in refractory metastatic colorectal cancer: characterization of high-response patients ﻿

Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases—the PURPLE trial ﻿

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer ﻿

Clinical validation of liquid biopsy-RECIST (LB-RECIST) in metastatic colorectal cancer (mCRC) patients: findings from the PLATFORM-B study ﻿

Epigenetic synthetic lethality as a cancer therapeutic strategy: synergy of experimental and computational approaches ﻿

Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE ﻿

Spatial TCR clonality and clonal expansion in the in situ microenvironment of non-small cell lung cancer ﻿